The present invention provides compositions comprising fosfomycin for reducing or eliminating bacterial promoters of colorectal cancer from colorectal adenomas, polyps and adenocarcinomas, as well as from the associated bacterial biofilm, by local 5 administration into the bowel lumen.
The present invention provides compositions comprising as an essential feature granulocyte-macrophage colony-stimulating factor (GM-CSF) together with fosfomycin for the treatment of wounds, ulcers, sores, burns and other injuries to the skin or mucous membranes of the body.
A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
3.
COMPOSITION FOR THE INTRAPERITONEAL TREATMENT OF SECONDARY BACTERIAL PERITONITIS WITH REDUCTION OF COMPLICATIONS
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antibiotic agents to treat, pre-emptively treat or prevent infectious peritonitis or intra-abdominal infection and reduce the occurrence of local peritonitis or intra-abdominal abscess resulting therefrom by the intraperitoneal administration of the compositions.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Compositions are provided that target biological therapeutic agents to mucosal defects in the gastrointestinal tract by means of antacid mucosal protective agents that bind selectively to such defects.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
The present invention provides compositions comprising fosfomycin for reducing or eliminating bacterial promotors of colorectal cancer, whether in the tumor or biofilm, by local administration into the bowel lumen.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antibiotic agents to treat, pre-emptively treat or prevent infectious peritonitis or intra-abdominal infection and reduce the occurrence of local peritonitis or intra-abdominal abscess resulting therefrom by the intraperitoneal administration of the compositions.
Compositions are provided that target biological therapeutic agents to mucosal defects in the gastrointestinal tract by means of antacid mucosal protective agents that bind selectively to such defects.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor (GM-CSF), sucrose octasulfate or sucralfate and hyaluronic acid for the treatment, pre-emptive treatment or prophylaxis of ulcers, wounds and other injuries to the skin or membranes of the body. Other aspects of the invention are methods of treatment or prevention using the compositions described, as well as an application device for use in the methods provided.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antimicrobial agents for the treatment, pre-emptive treatment or prevention of infectious peritonitis or intra-abdominal infection by intraperitoneal administration of the compositions.
The present invention provides compositions comprising fosfomycin for reducing or eliminating bacterial promotors of colorectal cancer, whether in the tumor or biofilm, by local administration into the bowel lumen.
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
11.
Methods and compositions for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy
Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and fosfomycin for the treatment, prevention or alleviation of an inflammatory bowel disease such as Crohn's disease, ulcerative colitis or necrotizing enterocolitis of newborn and premature infants by administration of the compositions into the intestinal lumen.
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antimicrobial agents for the treatment, pre-emptive treatment or prevention of infectious peritonitis or intra-abdominal infection by intraperitoneal administration of the compositions.
A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
14.
COMPOSITIONS COMPRISING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and fosfomycin for the treatment, prevention or alleviation of an inflammatory bowel disease such as Crohn's disease, ulcerative colitis or necrotizing enterocolitis of newborn and premature infants by administration of the compositions into the intestinal lumen.
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor (GM-CSF), sucrose octasulfate or sucralfate and hyaluronic acid for the treatment, pre-emptive treatmentor prophylaxis of ulcers, wounds and other injuries to the skin or membranes of the body. Other aspects of the invention are methods of treatment or prevention using the compositions described, as well as an application device for use in the methods provided.
The present invention provides compositions comprising as an essential feature granulocyte-macrophage colony-stimulating factor (GM-CSF) together with fosfomycin for the treatment of bacterial lung infections by administration via the airways.
The present invention provides compositions comprising as an essential feature granulocyte-macrophage colony-stimulating factor (GM-CSF) together with fosfomycin for the treatment of wounds, ulcers, sores, burns and other injuries to the skin or mucous membranes of the body.
The present invention relates to granulocyte-macrophage colony-stimulating factor (GM-CSF) for use in the treatment of severe forms of bronchial asthma by administering via the airway an effective amount of GM-CSFor a functional homologue thereof.
Granulocyte-macrophage colony stimulating factor for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy
Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
patents
